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Background: Bacteria contribute considerably to the progression of lung disease in cystic fibrosis. In this prospective, multi-centre
study, we aimed to evaluate the occurrence of emerging bacteria and the physicians’ assessments of the clinical importance of these
findings.
Methods: Twelve CF centres (total number of patients: 1419) reported the detection of any Stenotrophomonas maltophilia,
Burkholderia cepacia complex, MRSA, Alcaligenes xylosoxidans, Klebsiella species and Mycobacteria during an observation period of
6 months.
Results: 213 specimens with emerging bacteria were reported from 145 different patients. The proportion of patients with emerging
bacteria differed between centres (3–38%, mean: 12.6%) and increased with age. The predominant bacterium was S. maltophilia (n=106
positive specimens), followed by Klebsiellae (n=36), B. cepacia complex (n=31), A. xylosoxidans (n=16), Mycobacteria (n=11), MRSA
(n=11), and others (n=2). In many instances the same microorganisms had already been reported earlier, indicating intermittent or
chronic colonisation. The clinical status was reported to be stable in 70% of patients, and antibiotic treatment was anticipated for 46%
of positive specimens. Comparison of clinical data to age matched controls did not reveal any significant differences with regard to
pulmonary and nutritional status prior to detection of emerging bacteria.
Conclusion: These data suggest a high variability between centres regarding the prevalence of emerging bacteria. Most patients
maintained a stable clinical condition during the 6-month study period despite being colonised with emerging bacteria.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Keywords: S. maltophilia; Registry; Prospective survey; Incidence; Prevalence1569-1993/$ - s
doi:10.1016/j.jcf
T Correspondi
E-mail addr
1 D. Staab, Ch
University of Ha
Hamburg-Altona
Hospital, Unive
Cologne. J. Bars 4 (2005) 41–48ee front matter D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
.2004.10.002
ng author. Schellingstr. 5a, D-30625 Hannover, Germany. Tel.: +49 511 533 28 12; fax: +49 511 533 28 13.
ess: steinkamp@med-wiss.com (G. Steinkamp).
ildren’s Hospital, Charite´, Humboldt University, Berlin. F. Ratjen, Children’s Hospital, University of Essen. S. Brfmme, Children’s Hospital,
lle. H. Lindemann, Children’s Hospital, University of Giessen. H. B7rmeier, Children’s Hospital, University of Erlangen. H. Heuer, CF-Centre
. H.G. Posselt, Children’s Hospital, University of Frankfurt. G. Dockter, Children’s Hospital, University of Homburg. A. Schuster, Children’s
rsity of Dqsseldorf. T. Nqglein, Children’s Hospital, University of Bochum. S. van Koeningsbruggen, Children’s Hospital, University of
gon, Department of Internal Medicine, University of Frankfurt.
G. Steinkamp et al. / Journal of Cystic Fibrosis 4 (2005) 41–48421. Introduction
Bacterial pathogens contribute considerably to morbidity
and mortality in patients with cystic fibrosis [1]. The
microbial flora in the airways includes many different
organisms. Major pathogens are Staphylococcus aureus,
Pseudomonas aeruginosa, and Haemophilus influenzae. In
children aged 6–10 years, colonisation rates for these
bacteria have been reported to be 60%, 40%, and 25%,
respectively [2]. The majority (80%) of adults are chroni-
cally infected with P. aeruginosa, and 35% harbour S.
aureus in their airways.
In recent years, the emergence of bacteria such as
Burkholderia cepacia complex, Stenotrophomonas malto-
philia, Methicillin resistant S. aureus (MRSA), Alcaligenes
xylosoxidans, Klebsiella species and non-tuberculous myco-
bacteria (NTM) has been reported with increasing frequency
[3]. Within this group of bacteria B. cepacia complex has
caused particular concern, since some strains are associated
with a significant decline in lung function or even
respiratory failure and death [4]. In addition, these
pathogens can be transmitted between patients, and have
led to outbreaks in individual CF centres [5]. The prevalence
rate of B. cepacia complex in Germany was 2.4% in 2000
[6], and the percentage of colonised patients increased with
age and parallel to the severity of lung disease.
Approximately 10% of CF patients are colonised with S.
maltophilia [2]. These bacteria are resistant to different
classes of antibiotics, and previous treatment with anti-
microbials has been identified as a predisposing factor for S.
maltophilia colonisation [7]. In previous reports 80% of
patients were colonised for less than 12 months, and S.
maltophilia may also cause chronic colonisation of the
airways (26). Neither pulmonary function nor survival rate
has been shown to be affected by S. maltophilia colonisa-
tion [8,9].
MRSA represents another microorganism, which is
found in increasing frequency in CF patients. Prevalence
rates of up to 17% have been reported in some centres [2].
Poor pulmonary function and previous hospitalisation have
been identified as risk factors for MRSA colonisation [10].
To prevent nosocomial transmission, patients need to be
isolated during hospitalisation and at the clinical setting. As
for patients colonised with B. cepacia complex, these social
implications represent a considerable burden for affected
individuals.
Only limited information is available on the clinical
relevance of Klebsiella species and A. xylosoxidans. While
in one report, A. xylosoxidans were associated with acute
pulmonary exacerbations [11], no apparent decline in
clinical status was observed after long-term colonisation in
another study [12].
Most reports on emerging bacteria focus on one or two
microorganisms, or present data from a single cystic fibrosis
centre. Case report forms of national cystic fibrosis
registries do not routinely request specific information onthese bacteria. A prospective evaluation of the emergence of
emerging bacterial across different centres has not been
reported.
We aimed to document the occurrence of emerging
bacterial in German CF centres, to report the physicians’
assessments of the clinical importance of these findings, and
to evaluate the patient’s clinical status at colonisation.2. Patients and methods
2.1. Questionnaire
The one-page questionnaire contained information on the
present bacteriologic findings, and asked the physician to
assess the implications of these results for the care of the
patient. For example, we asked whether the clinical status of
the patient was considered stable, better, or worse compared
with that of the preceding 6 months, whether earlier
monitoring of the bacterial findings was anticipated, whether
antibiotic treatment aimed at the respective bacterium was
planned, and if so, which drug was selected. With respect to
the colonisation with other microorganisms during the
preceding 12 months, physicians were asked to indicate
whether these bacteria had ever been detected before, or
whether colonisation was intermittent or chronic (intermit-
tent: V50%, chronic: N50% of samples were positive for the
bacterium during the previous 12 months, respectively).
Potential risk factors for bacterial colonisation were also
recorded, for example, recent hospitalisation or treatment at a
rehabilitation centre, treatment with inhaled, oral, or intra-
venous antibiotics within the preceding 6 months, or if a CF
sibling was colonised with the same bacteria.
2.2. Epidemiologic Registry of Cystic Fibrosis (ERCF)
This CF patient Registry was founded in 1995, as
previously described [13]. It contains anonymous patient
data from each visit of a patient at a CF centre. Most patients
had three monthly intervals between routine centre visits.
Data were regularly transferred into the ERCF database by
remote data entry. For the present project, all participating
centres gave their written permission to use the ERCF data
for statistical analyses.
2.3. Participating centres
Twelve CF centres participated in the project. Eleven of
these treated CF patients from all age groups, whereas one
centre treated adult patients only. The number of patients in
each centre ranged from 62 to 199, and the total number was
1419 patients, which is more than one third of all patients
registered in the German CF quality assurance project [6].
One centre later decided not to use its ERCF data for the
clinical part of the study, and one centre did not report data to
the ERCF, so that only data from ten CF centres were
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their regular laboratory for the identification of pathogens in
sputum or throat swabs, and no standardisation between
laboratories was attempted for the purpose of the study.
2.4. Study protocol
During a period of 6 months, from July 1st to December
31st, 2000, physicians prospectively recorded the occur-
rence of any emerging bacteria detected in specimens from
sputum or throat swabs. For the purpose of the study,
emerging bacteria such as Alcaligenes species, Klebsiellae,
Mycobacteria, B. cepacia complex, or multiresistant S.
aureus (MRSA), were explicitly mentioned. For the
documentation of other bacteria, the physician used free
text. After filling in all information on the bacteriologic
findings, the physician faxed the sheet to the study centre.
To keep the extra workload for the participating centres as
low as possible, clinical data were not included in the
questionnaire, but taken from the computerised ERCF
Registry (see above), using the patient ID as a link.
2.5. Microbiology
Respiratory tract specimens were assessed in the local
microbiology laboratories of each centre. The methods were
not standardised for the present study, but the laboratories
worked according to recommendations by German and
International expert groups. The participating CF-centres
had been approved by the German CF Foundation
(Mukoviszidose e.V.), which requires minimal standards
for microbiologic test procedures. The following description
may serve as a typical example for the methods used in the
present study.
Sputum samples or throat swabs were inoculated on non-
selective sheep blood agar and selective solid media such as
chocolate agar with bacitracin, McConkey-agar, B. cepacia
selective agar (BCSA) containing polymyxin, gentamicin
and vancomycin, ChromagarR (CROMagar, Paris, France),
and Sabouraud-Agar and into a liquid medium (glucose
bouillon) for conventional bacteriological and mycological
culture. These media were incubated for at least 5 days with
daily inspection and subcultivation, if necessary. A second
portion of the specimen was pre-treated with N-acetyl-l-
cystein-NaOH and inoculated on Lfwenstein-Jensen and
Middlebrook solid media and into Mycobacteria Growth
Indicator Tube (MGITR) culture bottles (Becton Dickinson,
Heidelberg, Germany) for the detection of non-tuberculous
mycobacteria such as Mycobacterium avium complex.
These media were incubated for eight weeks, with frequent
inspection of solid media and continuous measuring the
MGITR media by an automated growth detection system
(BACTECR-MGITR, Beckton Dickinson).
Colonies from presumed respiratory tract pathogens were
subcultivated onto suitable media for species identification
and antibiotic susceptibility testing [14].S. aureus was subcultivated onto blood- or CN-agar
(containing colistin and nalidixic acid) and identified by
colony morphology and a positive PastorexR Staph-Plus
test (Bio-Rad, Munich, Germany). If susceptibility testing or
subculture on oxacillin-containing media was suggestive of
MRSA, an additional test (MRSA-Screen, Denka Seiten,
Oakthorpe, UK) was performed. This latex agglutination
test detects for the existence of a modified penicillin-
binding-protein (PBP2a) that is responsible for methicillin-
resistance. A mecA-specific PCR (polymerase chain reac-
tion) was employed for confirmation of MRSA.
Gram-negative rods, selectively growing on McConkey
agar, were identified by morphological and biochemical
characteristics. P. aeruginosa was identified by a positive
oxidase test, growth at 42 8C and the production of specific
pigments such as pyocyanin. Enterobacteriaceae such as
Klebsiella species and some common nonfermentative
gram-negative rods such as S. maltophilia were identified
by manual (ApiR 20 E/NE, bioMe´rieux, Nqrtingen, Ger-
many) or automated (VitekTwoR, bioMe´rieux) biochemical
testing. Rare nonfermentative gram-negative rods such as
Alcaligenes (Achromobacter) xylosoxidans were also iden-
tified by ApiR 20 NE as were Burkholderia spp. at the genus
level. Burkholderia species at the species level were
identified by amplification of bacterial 16S rRNA combined
with sequence analysis followed by database comparison.
Non-tuberculous mycobacteria grown on Lfwenstein-
Jensen, Middlebrook or MGITR media were identified after
subculture using genus-specific probes or 16S rRNA-PCR.
Antimicrobial susceptibility testing of S. aureus and
fermentative gram-negative rods was performed according
to the National Committee for Clinical Laboratory Stand-
ards (NCCLS) using antibiotic disc assays or VitekTwoR
[15], whereas nonfermentative gram-negative rods including
P. aeruginosa, A. xylosoxidans and S. maltophilia were
tested by EtestR-strips (AB BIODISK, Solna, Sweden) [16].
2.6. Data base and statistical analysis
Each participating CF centre mailed a CD-ROM con-
taining its Registry data to the study centre. The ERCF
database had been programmed in SAS (SAS Institute Inc.,
Cary, NC, USA). A new database was built up in SPSS
(Chicago, IL, USA) for the information contained in the
questionnaires. Using the ERCF patient number, retrieval
was written to extract relevant data from the SAS file.
For each index patient with emerging bacteria, a
comparable partner was searched in order to permit a
matched pair analysis, using the criteria centre, sex, and age.
Most statistical analyses were performed in SPSS. The
clinical status at the time of identification of emerging
bacteria and within the preceding 12 months was compared
between index and control patients using unpaired Student’s
t-tests with two-tailed P values of 0.05. Chi- square tests
were used to compare the frequency of bacteria between
sexes, different age groups, or centres. Differences for age at
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Fig. 1. Previous reporting of identical bacterial species. Initial: The same
bacteria have never been reported within the last 12 months. Intermittent:
The same bacteria were reported at least once within the last 12 months.
Chronic: The same bacteria were reported in each specimen obtained within
the last 12 months.3. Results
3.1. Patients with emerging bacteria
Within the 6 months time period, 145 patients with
emerging bacteria were reported, corresponding to 10% of
the total number of 1419 patients in the participating centres
(Table 1). However, since two centres (E and L) did not
provide data from the ERCF Registry, and not every patient
visited the centre within the study period, the number of
patients with bacteriologic findings was considerably
smaller (n=794). The proportion of patients with emerging
bacteria in relation to all patients with bacteriologic findings
differed between centres, with a range of 3% to 38% (mean:
12.6%). A larger proportion of adults (19.2%) harboured
emerging bacteria than children and adolescents (10.5%).
Both sexes were equally affected.
Potential risk factors for colonisation with emerging
bacteria were documented in the questionnaire. 29% of
patients had been hospitalised during the preceding 6
months, 14% had siblings with CF and 10% had CF siblings
with similar bacteria, and 12% had been admitted to a
rehabilitation centre within the preceding 6 months. The vast
majority of patients (92%) had received antibiotics within
this time period. This was a considerably larger proportion
than in the total group of n=3497 patients from German CF
centres registered in the ERCF, of whom only 53% had
received antimicrobials in the year 2000. Individuals had
been treated with different inhaled, intravenous, or oral
drugs. Inhaled tobramycin (29%), intravenous ceftazidime
(22%), inhaled colistin (21%), and oral ciprofloxacin (19%)
were used most frequently in the present study.Table 1
Patients with emerging bacteria per centre
Centre Patients with
emerging
bacteria (n)
Number of
patients in
centre (n)
Patients with
bacteriologic
findings in the
registry (n)
Patients with
emerging
bacteria in the
registry (n, %)
A 28 199 135 23 (17%)
B 6 171 49 3 (6%)
C 10 194 115 7 (6%)
D 16 97 82 14 (17%)
Ea 13 – – –
F 9 173 118 9 (8%)
G 11 131 101 8 (8%)
H 2 96 78 2 (3%)
I 6 62 27 5 (19%)
J 5 68 25 5 (20%)
K 29 141 64 24 (38%)
La 10 87 – –
145 1419 794 100 (12.6%)
a These centres did not report ERCF (bregistryQ) data.3.2. Bacterial species
A total number of 213 specimens with emerging bacteria
were documented. S. maltophilia were most frequently
reported (n=106 positive specimens). Other bacteria were
Klebsiellae (n=36), B. cepacia complex (n=31), Alcaligenes
(n=16), Mycobacteria (n=11), MRSA (n=11), and others
(n=2). Fig. 1 shows that in many instances the same
microorganisms had already been reported earlier, indicating
that intermittent or chronic colonisation with these bacteria
is not uncommon. Concomitant colonisation/infection with
other bacteria that are typical for CF occurred frequently
(58% for P. aeruginosa, and in 43% for S. aureus). Patients
with Alcaligenes and B. cepacia complex colonisation had a
greater proportion of concomitant P. aeruginosa infection
( pb0.05) than patients with other bacteria.
3.3. Physicians’ assessments of clinical impact
We asked the physicians to assess the clinical impact of
the detected bacteria. The clinical status of the patient
compared to the preceding 6 months was reported to be
stable in 70%, improved in 7% and deteriorated in 23% of
patients. This assessment reflected the clinical judgement of
the CF physicians, since no definition of deterioration was
used in the study. Physicians planned earlier monitoring of
bacterial specimens in 38% and antibiotic treatment in 46%
of positive specimens. Fig. 2 shows the responses grouped
by bacterial species. Earlier monitoring was planned in all
patients harbouring mycobacteria, but in only 26% with B.
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Fig. 2. Physician’s assessment of emerging bacteria.
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with mycobacteria, but only in 18% of MRSA.
3.4. Matched pair analysis
Clinical data from the ERCF Registry were available for
100 patients with emerging bacteria (Table 1) and were used
to compare patients with emerging bacteria with control
patients matched by centre, sex, and age (n=100). Table 2
shows the health status of the two patient groups. No
significant differences were found, indicating adequate
matching. Patients with emerging bacteria were more likelyTable 2
Matched pair analysis of patients with and without emerging bacteria
Patients with
emerging bacteria
(n=100)a
Patients without
emerging bacteria
(n=100)a
p-value
(two-sided)
Age 19F11 18F9 0.762
Sex (male:female) 49:51 49:51 1.0 (*)
Length (cm) 157F22 156F21 0.803
Body weight (kg) 42F21 41F18 0.862
FVC (l) 2.6F1.3 2.7F1.3 0.723
FEV1 (l) 1.9F0.9 2.0F1.1 0.606
FEF25-75 (l) 1.6F1.1 1.7F1.4 0.640
IgG (mg/dl) 13.3F5.4 14.2F7.5 0.432
Bacteriology: no
other pathogen
(% of patients)
8.2 14.7 0.178
P. aeruginosa
(% of patients)
42.9 41.1 0.216
S. aureus
(% of patients)
25 37 0.085
Specimen
(sputum:throat
swab, %)
56:44 39:61 0.029
a The number of patients differed between tests.to be sputum producers, but this was not associated with
differences in pulmonary function (Table 2). A trend
towards more frequent colonisation with S. aureus was
observed in index patients. CFTR mutation analysis
revealed that 60.7% of patients with emerging bacteria
were homozygous for the Delta F508 mutation in compar-
ison to only 23.8% of the control group (however, only 49
of the 200 matched cases had their genotype reported in the
registry). No significant differences were found between
index patients and controls with respect to treatment with
inhaled antibiotics, oral antibiotics, oral corticosteroids,
inhaled corticosteroids, or the frequency of diabetes
mellitus.
The clinical course preceding the onset of colonisation
with emerging bacteria was compared in a subgroup of
patients who had their first positive detection of emerging
bacteria within the observation period (n=43). Individual
patient data were pooled for three 6-month periods: 0–6
months before, 6–12 months before, and 0–6 months after
initial detection of emerging bacteria. No significant differ-
ences between patients with and without emerging bacteria
were observed for weight, height, forced vital capacity,
FEV1, MEF25-75, or immunoglobulin G, before and after
initial colonisation (data not shown).
3.5. Matched pair analysis of patients with and without S.
maltophilia
To evaluate a more homogenous group of patients, the
analyses mentioned above were repeated in those patients
who had the first positive culture for S. maltophilia
documented during the observation period (Table 3).
Disease severity did not differ between these patients and
a comparison group of non-colonised patients matched by
sex, age and centre. In contrast to the total group of patients
Table 3
Initial colonisation with S. maltophilia during the observation period:
matched pair analysis
Index
patients
(n=27)a
Control
patients
(n=27)a
p-value
(two-sided)
Age 15.7F7.9 16.0F8.3 0.927
Length (cm) 153F26 153F23 0.987
Body weight (kg) 36.5F23.0 35.7F18.3 0.923
FVC (l) 2.5F1.3 2.5F1.1 0.991
FEV1 (l) 1.9F1 1.8F0.9 0.903
FEF25–75 1.7F1.3 1.9F1.5 0.595
IgG (mg/dl) 13.2F4.8 13.9F8.4 0.696
Specimen
(sputum:throat swab, %)
50:50 33:67 0.340
a The number of patients differed between tests.
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specimens (sputum or throat swabs) was similar in patients
with and without S. maltophilia. The clinical status of
colonised patients within 12 months before and 6 months
after the date of initial colonisation did not differ from those
without S. maltophilia with respect to weight, height, IgG,
and pulmonary function.4. Discussion
In this study we evaluated the frequency of emerging
bacteria in 12 German CF centres as well as the physician’s
perception of their clinical relevance. Emerging bacteria
were found in approximately 10% of patients and were more
prevalent in adult CF patients. Colonisation with these
bacteria was associated with the use of antibiotics;
particularly those directed against P. aeruginosa. The
majority of patients were considered to be in clinically
stable condition as judged by their physician. Comparison
of clinical data to age matched controls did not reveal any
significant differences with regard to their pulmonary and
nutritional status.
Although this study was performed in a relatively large
cohort of patients, it has a number of limitations. The survey
was performed over a period of only 6 months and may
therefore not reflect the overall prevalence of these bacteria
in the population. The clinical relevance of these bacteria
relied on the information given by the patient’s physicians
and may not adequately reflect their clinical status. The
overall frequency for all bacteria except S. maltophilia was
rather small and was not confirmed by a central micro-
biologic laboratory. However, the survey did provide some
interesting insights on how CF physicians deal with positive
cultures for these bacteria, as in most instances the presence
of these bacteria was not considered to be relevant for the
individual patient and did not result in changes in the
patient’s therapy.
S. maltophilia was by far the most frequent of the group
of bacteria studied. Interestingly, we could study asubgroup of patients who newly acquired the bacterium.
Similar to previous reports we could not observe any short-
term effect of S. maltophilia on lung function in CF
patients [9,17]. Because of the short observation period, we
can, however, not exclude that long term infection with S.
maltophilia may have a negative impact on the course of
lung disease in CF.
Several factors have been postulated to increase the risk
of S. maltophilia in CF patients. These include poorer
clinical status associated with more intense regimens of
antibiotic treatment. While the role of inhaled antibiotics
such as tobramycin is controversial [18], oral ciprofloxacin
has been postulated to be a risk factor for subsequent
colonisation with S. maltophilia [19]. In the present study, 9
of the 31 patients (29%) who had the first positive culture
for S. maltophilia documented during the observation
period had used ciprofloxacin, in comparison to 17% of
patients without S. maltophilia colonisation ( p=0.13).
These data do not support a causal relationship between
the two events. The use of antibiotics in the present study
was not systematically different from that in the German
part of the ERCF registry, although intravenous antibiotics
and oral cefaclor were used more frequently in patients with
emerging bacteria.
B. cepacia complex is known to be a relevant pathogen
in CF, at least in a subgroup of patients who develop a
massive inflammatory response [20,21]. The prevalence of
this group of pathogen was relatively low in our study
making it difficult to assess the clinical relevance within
this patient population. It has been well documented that
particularly Genomovar III (also called B. cenocepacia)
may have a negative impact on the course of lung disease,
whereas the clinical relevance of other genomovars is less
well established [22,23]. Unfortunately, genomovar analy-
sis was not available for patients included in this study,
and this is undoubtfully one of the limitations of this
study. Since the identification of B. cepacia complex
bacteria is notoriously difficult, national and European
reference centres have recently been established, which
provide an identification service for these bacteria. Data
from one German centre included in this analysis would
indicate that genomovar I occurs with the highest
frequency in Germany whereas genomovar III tends to
be rare [24]. This may explain that infection with B.
cepacia complex in this study did not have a demonstrable
effect on clinical outcome.
The incidence of non-tuberculous mycobacteria (NTM)
was low in this population. This is in agreement with former
studies performed in Central or Northern Europe, whereas a
higher incidence is found in some regions in the US [25–
27]. The detection of NTM prompted further testing in the
majority of patients in this study, which is different to all the
other bacteria included in this survey. This may reflect the
fact that the diagnosis of disease caused by NTM cannot be
based on a single culture result, since contamination occurs
relatively often. On the other hand, testing for NTM is not
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preferentially in patients who showed clinical deterioration
and in whom NTM related disease was suspected. Since the
number of patients harbouring NTM was low, we could not
further assess this question in this study.
The prevalence of MRSA was low in this population;
lower than reported in previous studies from the UK [28].
Chronic use of anti-staphylococcal antibiotics has been
postulated to be a risk factor for MRSA acquisition, and the
differences in prevalence may be influenced by the smaller
proportion of patients receiving continuous anti-staphylo-
coccal antibiotics. The role of anti-staphylococcal anti-
biotics for the development of MRSA is not clearly
established. Similar to previous reports [10,28], where CF
patients with MRSA were compared to patients with
methicillin sensitive strains, we could not find any
significant clinical effect of this bacterium. However, a
larger population needs to be studied to clarify its role in CF
lung disease.
The relevance of Alcaligenes and Klebsiella species in
CF lung disease is poorly understood. We have found these
bacteria in a significant proportion of patients with no
apparent effect on their clinical course. However, it is rather
difficult to distinguish colonisation from infection, and both
bacteria have been found to be detected only intermittently
in the majority of CF patients [11,12]. Whether a subgroup
of patients exists, in whom chronic infection with these
bacteria is clinically relevant, remains to be determined.
We found a high variability in the CF physician response
to the detection of all bacteria included in this analysis. This
may be due to differences in therapeutic strategies between
centres or may simply reflect the fact that the clinical
relevance of these bacteria is poorly understood. However,
we also observed considerable variability in the frequency
of these bacteria between different centres that was not
explained by variations in the patient populations. Whether
this is caused by differences in the quality of microbiology
laboratories, differences in antibiotic treatment or endemic
occurrence of bacteria in certain centres is presently unclear.
A structured approach assessing these differences over
extended periods seems warranted to better define risk
factors for colonisation with these bacteria.References
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